In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $60.00. The company’s shares closed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback